

Tuvirumab

Cat. No.:	HY-P99541
CAS No.:	138660-97-6
Target:	HBV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity ($K=3.6$ nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research ^{[1][2]} .
In Vivo	<p>Tuvirumab (OST 577; SDZ-OST 577; 5 mg/kg; iv; single dose) followed by intravenous wild-type HBV, the MS-2 strain, directs against the a determinant of HBV surface antigen delayed but does not prevent experimental infection of HBV and hepatitis in the chimpanzee^[1].</p> <p>Tuvirumab (5 mg/kg; iv) has a half-life of 16.7 days in the chimpanzee^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. N Ogata, et al. Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3014-8.
- [2]. RA Heijntink, et al. Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes. J Med Virol. 2001 Aug;64(4):427-34.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA